Moexipril is a prodrug of the long-acting angiotensin converting enzyme (ACE) inhibitor moexiprilat (IC₅₀s = 2.1 nM and 2.7 µM for moexiprilat and moexipril, respectively). In addition to its antihypertensive activity, moexipril has been identified as a phosphodiesterase 4 inhibitor (IC₅₀ = 38 µM for the PDE4B2 isoform) that increases cAMP in cells.